Difference between revisions of "Triptorelin (Trelstar LA)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
Line 1: | Line 1: | ||
− | |||
− | |||
==General information== | ==General information== | ||
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.<ref name="insert">[http://www.pfizer.com/files/products/uspi_trelstar_la.pdf Triptorelin (Trelstar LA) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/triptorelin.pdf Triptorelin (Trelstar LA) package insert (locally hosted backup)]</ref> | Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.<ref name="insert">[http://www.pfizer.com/files/products/uspi_trelstar_la.pdf Triptorelin (Trelstar LA) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/triptorelin.pdf Triptorelin (Trelstar LA) package insert (locally hosted backup)]</ref> | ||
Line 9: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
+ | *[[Breast cancer]] | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
Line 17: | Line 16: | ||
* 6/15/2000: Initial FDA approval "in the palliative treatment of advanced [[Prostate cancer | prostate cancer]]." | * 6/15/2000: Initial FDA approval "in the palliative treatment of advanced [[Prostate cancer | prostate cancer]]." | ||
+ | ==Also known as== | ||
+ | *'''Brand names:''' Decapeptyl, Diphereline, Gonapeptyl, Trelstar LA, Variopeptyl | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
+ | [[Category:Intramuscular medications]] | ||
+ | |||
[[Category:Endocrine therapy]] | [[Category:Endocrine therapy]] | ||
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
[[Category:GnRH agonists]] | [[Category:GnRH agonists]] | ||
+ | [[Category:Breast cancer medications]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:FDA approved in 2000]] | [[Category:FDA approved in 2000]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] |
Revision as of 20:35, 22 August 2018
General information
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.[1][2]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 6/15/2000: Initial FDA approval "in the palliative treatment of advanced prostate cancer."
Also known as
- Brand names: Decapeptyl, Diphereline, Gonapeptyl, Trelstar LA, Variopeptyl